𝐔𝐧𝐝𝐞𝐫𝐬𝐭𝐚𝐧𝐝𝐢𝐧𝐠 𝐠𝐞𝐧𝐞𝐬 𝐟𝐨𝐫 𝐛𝐞𝐭𝐭𝐞𝐫 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭
Pharmacogenomics focuses on genomic information to optimize treatment efficacy and minimize adverse drug reactions. It studies how an individual’s genetic makeup influences their response to drugs.
𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐃𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬: 𝐌𝐚𝐭𝐜𝐡𝐢𝐧𝐠 𝐭𝐡𝐞 𝐑𝐢𝐠𝐡𝐭 𝐃𝐫𝐮𝐠 𝐭𝐨 𝐭𝐡𝐞 𝐑𝐢𝐠𝐡𝐭 𝐏𝐚𝐭𝐢𝐞𝐧𝐭
Companion diagnostics are tests closely linked to the expected effectiveness of a particular drug. The use of these tests precedes prescribing the drug and aids in predicting the likelihood of success of the treatment.
𝐀 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧: 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐨𝐠𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐚𝐧𝐝 𝐍𝐆𝐒 𝐟𝐨𝐫 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞
𝐍𝐆𝐒 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜𝐬 𝐟𝐨𝐫 𝐨𝐯𝐚𝐫𝐢𝐚𝐧 𝐜𝐚𝐧𝐜𝐞𝐫 𝐚𝐬 𝐚𝐧 𝐞𝐱𝐚𝐦𝐩𝐥𝐞:
These assays enabled the detection of 𝘉𝘙𝘊𝘈1/2 alterations in ovarian tumor tissues to help identify cancer patients for whom treatment with RubracaTM (rucaparib) can be more effective.
Tests like BRACAnalysis CDx (Myriad) and FoundationFocus CDxBRCA (Foundation Medicine) use NGS for single-gene sequencing.
These tests target 𝘉𝘙𝘊𝘈1 and 𝘉𝘙𝘊𝘈2 mutations in ovarian tumors.
Identifying these mutations helps to determine if a patient might benefit more from treatment with Rubraca™ (rucaparib).
Precision oncology, fueled by these advancements, is revolutionizing cancer care. As NGS technology becomes faster and more affordable, it’s becoming a standard tool in diagnosing and treating cancer. This, along with continued research in pharmacogenomics, paves the way for the development of even more effective and personalized cancer treatments.
